“Wow! Badass. 13,200 crispr base edits in a single cell! On the way to ‘recoded’ human cells,” tweeted Antonio Regalado before covering the news in MIT Technology Review. To be honest, the radical redesign of species is still sci-fi dystopia, but the paper preprinted by Cory J. Smith et al. in bioRxiv is impressive anyway. Continue reading
There is hardly any day without CRISPR news. February starts with researchers correcting abnormalities associated with Duchenne muscular dystrophy (Science Advances) and performing allele-specific editing in blind mice (bioRxiv, forthcoming in The CRISPR Journal). A repechage from January also: how to get pluripotent stem cells by CRISPRing just one gene (Cell Stem Cell).
It was August 2 when Nature published the latest stunning study, introducing to the world the first human embryos edited in the US by Shoukhrat Mitalipov. Not even a month had passed, and on August 28, those results have been challenged on a much younger and quick medium: the bioRxiv pre-print website. I felt like a déjà vu happening. It reminded me of the Nature Methods study questioning CRISPR’s precision in June. Within three weeks bioRxiv has already challenged the controversial data about off-target mutations by posting two critical analyses which soon became three. In short, this server is rewriting a part of CRISPR’s science and it is becoming an emergency tool for correcting mistakes that, inevitably, sometimes tarnish the most respected peer-reviewed publications. How does it work? Continue reading
Faster, better, cheaper is a motto adopted by Nasa that perfectly fits CRISPR as well. The most popular technique for genetic modification, in fact, has the reputation of being quick, affordable and precise. This deserved good name was unexpectedly tarnished by a study questioning the technology precision, published in the June issue of Nature Methods. However, reports about CRISPR’s demise have been greatly exaggerated, to paraphrase Mark Twain. Just over a month later, three analyses challenging the controversial study are already available in the pre-publication archive bioRxiv, and Nature Methods has alerted its readers about the criticisms received by publishing an editorial note which could turn into a retraction. Continue reading